Drug Profile
Omadacycline - Paratek Pharmaceuticals
Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Tufts University
- Developer Merck & Co; Paratek Pharmaceuticals; ZAI Lab
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Small molecules; Tetracyclines
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia; Skin and soft tissue infections
- Preregistration Anthrax
- Phase II Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Urinary tract infections
- Phase I Bacterial infections
- No development reported Acute sinusitis; Plague
- Discontinued Nosocomial infections
Most Recent Events
- 05 Mar 2024 Preclinical trials in Anthrax in USA (Inhalation) prior to March 2024
- 05 Mar 2024 Paratek Pharmaceuticals plans a meeting with US FDA to align on the final studies required to support the sNDA submission for both anthrax treatment and PEP indications in the middle of 2024
- 05 Mar 2024 Paratek Pharmaceuticals plans to file sNDA to US FDA for Anthrax and post-exposure prophylaxis (PEP)